# OnCo record rtog-9601 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/rtog-9601/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "rtog-9601", "NCT00002874" ;
  schema:name "RTOG 9601"@en ;
  schema:description "RTOG 9601 showed that adding two years of hormone therapy to salvage radiotherapy after prostate surgery lengthens survival, mainly in men with higher PSA levels at relapse."@en ;
  schema:url <https://onco.cc/trials/rtog-9601/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00002874>, <https://doi.org/10.1056/NEJMoa1607529> ;
  onco:status "positive" ;
  onco:tag "radiation-wave4" ;
  onco:phase "3" ;
  schema:startDate "1998-02" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/bicalutamide/> ;
  onco:companies <https://onco.cc/companies/nrg-oncology/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rtog-9601-n-engl-j-med-2017/> .